Briede Ieva, Narbute Inga, Kumsars Indulis, Sondore Dace, Trushinskis Karlis, Jegere Sanda, Latkovskis Gustavs, Strenge Karlis, Rudzitis Ainars, Erglis Andrejs
Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, University of Latvia, Riga, Latvia.
Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Postepy Kardiol Interwencyjnej. 2018;14(2):144-148. doi: 10.5114/aic.2018.76405. Epub 2018 Jun 19.
The aim of this long-term registry data was to evaluate 2-year clinical and angiographic outcomes after implantation of everolimus-eluting bioresorbable scaffolds (Absorb) from the Latvian Centre of Cardiology Real-life Registry.
Between November 2012 and December 2014 in the Centre of Cardiology Real-life Bioresorbable Vascular Scaffold Registry, 187 patients with stable angina or acute coronary syndrome and available 2-year follow-up were selected. All patients had percutaneous coronary intervention (PCI) following bioresorbable scaffold (Absorb) implantation. At 2 years, clinical parameters were analysed in stable angina and acute coronary syndrome subgroups: all-cause death, cardiac death, non-cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), scaffold thrombosis (ST), cerebral infarction, in-scaffold restenosis and bleeding.
The clinical follow-up rate at 2 years was 96.2%. In-hospital death occurred in 2 (1.1%) patients, and 1 (0.5%) patient had in-hospital MI. At 2 years, the rate of all-cause death was 3.9% ( = 7), MI 1.6% ( = 3), TLR 3.9% ( = 7), and TVR 8.4% ( = 15). Between hospital discharge and 2-year follow-up scaffold thrombosis occurred in 2 (1.1%) patients. In-hospital scaffold thrombosis occurred in 1 (0.5%) patient due to clopidogrel resistance, and 1 additional case of scaffold thrombosis occurred at 5 days after implantation (0.5%).
Bioresorbable scaffolds showed acceptable efficacy (target lesion revascularization) and safety (cardiac death, myocardial infarction, and scaffold thrombosis) results at mid-term follow-up in stable angina and acute coronary syndrome patients.
这项长期注册数据的目的是评估拉脱维亚心脏病学中心实际病例注册研究中，依维莫司洗脱生物可吸收支架（Absorb）植入术后2年的临床和血管造影结果。
在2012年11月至2014年12月期间，从心脏病学中心实际病例生物可吸收血管支架注册研究中，选取了187例患有稳定型心绞痛或急性冠状动脉综合征且有2年随访资料的患者。所有患者均在植入生物可吸收支架（Absorb）后接受了经皮冠状动脉介入治疗（PCI）。在2年时，对稳定型心绞痛和急性冠状动脉综合征亚组的临床参数进行分析：全因死亡、心源性死亡、非心源性死亡、心肌梗死（MI）、靶病变血运重建（TLR）、靶血管血运重建（TVR）、支架血栓形成（ST）、脑梗死、支架内再狭窄和出血。
2年时的临床随访率为96.2%。2例（1.1%）患者发生院内死亡，1例（0.5%）患者发生院内MI。在2年时，全因死亡率为3.9%（n = 7），MI为1.6%（n = 3），TLR为3.9%（n = 7），TVR为8.4%（n = 15）。在出院至2年随访期间，2例（1.1%）患者发生支架血栓形成。1例（0.5%）患者因氯吡格雷抵抗发生院内支架血栓形成，另外1例支架血栓形成发生在植入后5天（0.5%）。
在稳定型心绞痛和急性冠状动脉综合征患者的中期随访中，生物可吸收支架显示出可接受的疗效（靶病变血运重建）和安全性（心源性死亡、心肌梗死和支架血栓形成）结果。
